- Source type
- Government
- Access type
- Official
- Publisher
- U.S. Food and Drug Administration
- Date
- 2026
- Added
- 2026-07-05
Trust profile
VV Source Trust Matrix v1.0
VV Source Trust Matrix v1.0 asks whether this source is trustworthy for the claim lane being used, not whether every possible claim from it is equally strong.
94
U.S. health regulator
- Publisher type
- Regulator
- Bias profile
- Low
This source is strongest for regulatory status and safety and weaker for consumer context and trial discovery.
VV Source Fit Score 1.0
Fit by use case
Fit scores are role-specific. A source can be excellent for one claim lane and weak for another.
- Regulatory status
- 98/100
- Primary Anchor
- Clinical outcomes
- 84/100
- Strong Support
- Mechanism
- 68/100
- Context Source
- Safety
- 95/100
- Primary Anchor
- Consumer context
- 68/100
- Context Source
- Trial discovery
- 68/100
- Context Source
Best used for
- Approvals
- Labels
- Safety communications
Weak for
- Comparative effectiveness
- Consumer experience
Used in Viral Vitalism
FDA Expanded CRISPR Therapy to Children as Young as 2
Roles: Regulatory status
Related studies
No structured study record is currently attached to this source.
Related sources
ClinicalTrials.gov: first-in-human EPI-321 study in FSHD
Canonicalized from June 30, 2026 rapid-brief batch.
- Trust score
- 84
- Publisher
- ClinicalTrials.gov
- Access
- Official
- Usage
- 1 connection
UCSF Clinical Trials: NGN-401 Rett syndrome study
Canonicalized from June 30, 2026 rapid-brief batch.
- Trust score
- 84
- Publisher
- UCSF Clinical Trials
- Access
- Publisher
- Usage
- 1 connection
FDA: Casgevy expanded to young children with sickle cell disease
Primary regulatory source for the July 2026 Casgevy age-expansion brief.
- Trust score
- 94
- Publisher
- U.S. Food and Drug Administration
- Access
- Official
- Usage
- 1 connection
FDA: First Gene Therapies to Treat Patients with Sickle Cell Disease
Canonicalized from rapid brief daniel-cressy-sickle-cell-gene-therapy-louisiana.
- Trust score
- 94
- Publisher
- U.S. Food and Drug Administration
- Access
- Official
- Usage
- 2 connections
FDA: Draft Guidance to Help Accelerate Cell and Gene Therapies
Canonicalized from rapid brief fda-rare-disease-gene-therapy-flexibility.
- Trust score
- 94
- Publisher
- U.S. Food and Drug Administration
- Access
- Official
- Usage
- 1 connection
FDA: Leveraging Prior Knowledge in Gene Therapy Products Incorporating Genome Editing
Canonicalized from rapid brief fda-rare-disease-gene-therapy-flexibility.
- Trust score
- 94
- Publisher
- U.S. Food and Drug Administration
- Access
- Official
- Usage
- 1 connection